UK Medical Cannabis Registry: a case series analysing clinical outcomes of medicinal cannabis therapy for fibromyalgia
There was an association between treatment with CBMPs and improvements in pain, anxiety, sleep, and general quality of life. The high incidence of AEs in relation to other patient cohorts from the UKMCR may relate to the central sensitisation mechanism of fibromyalgia. Key Points • This study found that CBMPs were associated with short to medium-term improvements in pain, anxiety, sleep, and general quality-of-life in patients with fibromyalgia. • More randomised controlled trials are warranted to consolidate the literature, but this large analysis provides real-world data to inform their rollout.
Authors
- Azfer Usmani
- Ross Coomber (ORCID: https://orcid.org/0000-0002-8144-1996)
- Alia Darweish Medniuk
- Simon Erridge (ORCID: https://orcid.org/0000-0001-5871-6501)
- James Rucker (ORCID: https://orcid.org/0000-0003-4647-8088)
- Shelley Barnes
- Kaitlyn McLachlan (ORCID: https://orcid.org/0000-0003-4569-7529)
- Mohammed Sajad
- Michael Platt
- Wendy Holden
- Rahul Guru
- Eleanor Clarke (ORCID: https://orcid.org/0000-0002-2150-2283)
- S. L. Varma
- Robert Searle
- Atul Aggarwal
- Madhur Varadpande
Institutions
- Cardiff and Vale University Health Board (GB)
- North Bristol NHS Trust (GB)
- King's College London (GB)
- South London and Maudsley NHS Foundation Trust (GB)
- St George's Hospital (GB)
- St Mary's Hospital (GB)
- St Mary's Hospital (GB)
- Imperial College London (GB)
Publication Details
- Journal
- Clinical Rheumatology
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1007/s10067-025-07846-6
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00